NDA 204958 · Chiesi
Kengreal
Cangrelor · Intravenous · P2Y12 Platelet Inhibitor
NovelLast checked: Nov 20, 2026Latest source record: Jan 26, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Jun 22, 2015
Approved uses
1
Original approval plus efficacy supplements
Registered trials
30
4 Phase 3, 3 recruiting
FAERS reports
404
290 serious, 84 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 21, 2025.
KENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y 12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor [see Clinical Studies ( 14.1 )]. KENGREAL is a P2Y 12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y 12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor. ( 1 )
Mechanism: Cangrelor is a direct P2Y 12 platelet receptor inhibitor that blocks ADP-induced platelet activation and aggregation. Cangrelor binds selectively and reversibly to the P2Y 12 receptor to prevent further signaling and platelet activation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- KENGREAL · CANGRELOR 50MG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Cangrelor" as an intervention, any sponsor and status, largest first.
- A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)Pivotal-lookingCompleted
The Medicines CompanyIndustry
NCT01156571 · 11,145 participants · Start Sep 2010 · Primary completion Dec 2012
Drug: cangrelor P2Y12 (platelet) inhibitor; Clopidogrel - 300 or 600 mg (study arm) and 1 more · For: Atherosclerosis; Percutaneous Coronary Intervention; Acute Coronary Syndrome
Sites: Anderson, South Carolina
- A Clinical Trial to Demonstrate the Efficacy of CangrelorPivotal-lookingTerminated
The Medicines CompanyIndustry
NCT00305162 · 8,882 participants · Start Apr 2006 · Primary completion May 2009
Drug: Cangrelor (P2Y12 inhibitor); clopidogrel (oral P2Y12 inhibitor) and 3 more · For: Myocardial Infarction (MI); Acute Coronary Syndromes (ACS)
Sites: Philadelphia, Pennsylvania
- Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.Pivotal-lookingTerminated
The Medicines CompanyIndustry
NCT00385138 · 5,364 participants · Start Sep 2006 · Primary completion May 2009
Drug: Cangrelor; clopidogrel and 3 more · For: Atherosclerosis; Acute Coronary Syndrome (ACS)
Sites: Fargo, North Dakota
- Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial InfarctionPivotal-lookingCompleted
Faculty Hospital Kralovske VinohradyGovernment (non-federal)
NCT03551964 · 605 participants · Start Aug 1, 2018 · Primary completion Feb 19, 2024
Drug: Cangrelor; Ticagrelor · For: Acute Myocardial Infarction; Cardiogenic Shock
Sites: Prague, Czechia; Brno, Czechia; České Budějovice, Czechia · 29 sites in all
- REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEntsPivotal-lookingSuspended
Fondation Ophtalmologique Adolphe de RothschildResearch network
NCT04667078 · 368 participants (planned) · Start Mar 2, 2022 · Primary completion Dec 21, 2026
Drug: Cangrelor · For: Acute Ischemia
Sites: Besançon, France; Bordeaux, France; Bron, France · 13 sites in all
- Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCIPivotal-lookingCompleted
University of FloridaAcademic, hospital or other
NCT04668144 · 359 participants · Start Feb 18, 2021 · Primary completion Feb 2, 2023
Drug: Cangrelor; Prasugrel · For: Coronary Artery Disease; Acute Coronary Syndrome
Sites: Jacksonville, Florida
- Platelet Inhibition to Target Reperfusion InjuryPivotal-lookingStatus unknown
National Heart Centre SingaporeAcademic, hospital or other
NCT03102723 · 228 participants · Start Oct 1, 2017 · Primary completion Dec 2022
Drug: Cangrelor · For: STEMI
Sites: Singapore, Singapore · 5 sites in all
- Maintenance of Platelet Inhibition With CangrelorPivotal-lookingCompleted
The Medicines CompanyIndustry
NCT00767507 · 221 participants · Start Oct 2008 · Primary completion Jun 2011
Drug: cangrelor · For: Acute Coronary Syndrome (ACS)
Sites: La Jolla, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use160
- vascular stent thrombosis32
- drug ineffective31
- haemorrhage26
- death22
- no adverse event20
- cardiac arrest18
- inappropriate schedule of product administration18
- cardiogenic shock15
- gastrointestinal haemorrhage14
- dyspnoea12
- labelled drug-drug interaction medication error12
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 8 |
| 2014 | 2 |
| 2015 | 7 |
| 2016 | 19 |
| 2017 | 29 |
| 2018 | 22 |
| 2019 | 46 |
| 2020 | 55 |
| 2021 | 18 |
| 2022 | 28 |
| 2023 | 40 |
| 2024 | 53 |
| 2025 | 48 |
| 2026 | 22 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention: JACC Review Topic of the Week.
Sullivan AE, Nanna MG, Wang TY, et al. · J Am Coll Cardiol 2021 · Systematic Review
- Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.
Angiolillo DJ, Firstenberg MS, Price MJ, et al. · JAMA 2012 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Cangrelor for neurointerventional procedures: A systematic review.
Coulibaly NJ, Elgouhari MH, Arshad MH, et al. · Interv Neuroradiol 2026 · Systematic Review
- Variation in platelet expression of FcγRIIa after myocardial infarction.
McMahon SR, Chava S, Taatjes-Sommer HS, et al. · J Thromb Thrombolysis 2019 · Clinical Trial
- Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet (SWAP)-5 Study.
Franchi F, Ortega-Paz L, Rollini F, et al. · JACC Cardiovasc Interv 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effect of Cangrelor on Infarct Size in ST-Segment-Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (The PITRI Trial).
Bulluck H, Chong JH, Bryant J, et al. · Circulation 2024 · Randomized Controlled Trial, Multicenter Study
Sponsor: Chiesi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.